Left atrial appendage closure with transcatheter-delivered devices

Interventional Cardiology Clinics

Volumn 3, Issue 2, 2014, Pages 209-218

  Whisenant, Brian ^a   Weiss, Peter ^a  

^a INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Left atrial appendage; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; APIXABAN; CLOPIDOGREL; DABIGATRAN; EDOXABAN; NITINOL; POLITEF; POLYVINYL ALCOHOL; WARFARIN;

AMPLATZER CARDIAC PLUG; AMPLATZER VASCULAR PLUG; ANGIOGENESIS; ANTICOAGULANT THERAPY; BLEEDING; BLEEDING TENDENCY; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CLINICAL EFFECTIVENESS; CORONARY STENT; DEVICE APPROVAL; DEVICE SAFETY; DRUG CONTRAINDICATION; EMBOLISM; ENDOTHELIALIZATION; EXCISION; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART DISEASE; HEART EJECTION FRACTION; HEART SURGERY; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; LEFT ATRIAL APPENDAGE CLOSURE; LEFT ATRIAL APPENDAGE CLOSURE DEVICE; LEFT ATRIAL APPENDAGE EXCISION; LOW RISK POPULATION; MECHANICAL HEART VALVE; MEDICAL HISTORY; PATENT; PATIENT COMPLIANCE; PATIENT PREFERENCE; PERCUTANEOUS LEFT ATRIAL APPENDAGE TRANSCATHETER OCCLUSION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEPTAL OCCLUDER; SYSTEMIC DISEASE; SYSTEMIC EMBOLISM; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VASCULAR ENDOTHELIUM;

EID: 84897371305     PISSN: 22117458     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iccl.2014.01.002     Document Type: Review

References (40)

1. Lip G.Y., Frison L., Halperin J.L., et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke 2010, 41(12):2731-2738.
2. Granger C.B., Alexander J.H., McMurray J.J., et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365(11):981-992.
3. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
4. Patel M.R., Mahaffey K.W., Garg J., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365(10):883-891.
5. Giugliano R.P., Ruff C.T., Braunwald E., et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013, 369(22):2093-2104.
6. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285(22):2864-2870.
7. Gage B.F., van Walraven C., Pearce L., et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation 2004, 110(16):2287-2292.
8. Anderson J.L., Halperin J.L., Albert N.M., et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 61(18):1935-1944.
9. Lip G.Y., Nieuwlaat R., Pisters R., et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010, 137(2):263-272.
10. Connolly S.J., Eikelboom J., Joyner C., et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364(9):806-817.
11. Kirley K., Qato D.M., Kornfield R., et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 2012, 5(5):615-621.
12. Madden J.L. Resection of the left auricular appendix; a prophylaxis for recurrent arterial emboli. J Am Med Assoc 1949, 140(9):769-772.
13. Blackshear J.L., Odell J.A. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996, 61(2):755-759.
14. Lynch M., Shanewise J.S., Chang G.L., et al. Recanalization of the left atrial appendage demonstrated by transesophageal echocardiography. Ann Thorac Surg 1997, 63(6):1774-1775.
15. Kanderian A.S., Gillinov A.M., Pettersson G.B., et al. Success of surgical left atrial appendage closure: assessment by transesophageal echocardiography. J Am Coll Cardiol 2008, 52(11):924-929.
16. Sievert H., Lesh M.D., Trepels T., et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002, 105(16):1887-1889.
17. Ostermayer S.H., Reisman M., Kramer P.H., et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol 2005, 46(1):9-14.
18. Hanna I.R., Kolm P., Martin R., et al. Left atrial structure and function after percutaneous left atrial appendage transcatheter occlusion (PLAATO): six-month echocardiographic follow-up. J Am Coll Cardiol 2004, 43(10):1868-1872.
19. Omran H., Schmidt H., Hardung D., et al. Post mortem analysis of a left atrial appendage occlusion device (PLAATO) in a patient with permanent atrial fibrillation. J Interv Card Electrophysiol 2005, 14(1):17-20.
20. Block P.C., Burstein S., Casale P.N., et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) study. JACC Cardiovasc Interv 2009, 2(7):594-600.
21. Sick P.B., Schuler G., Hauptmann K.E., et al. Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2007, 49(13):1490-1495.
22. Fountain R.B., Holmes D.R., Chandrasekaran K., et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) trial. Am Heart J 2006, 151(5):956-961.
23. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 2009, 374(9689):534-542.
24. Maisel W.H. Left atrial appendage occlusion-closure or just the beginning?. N Engl J Med 2009, 360(25):2601-2603.
25. FDA. FDA executive summary: Boston Scientific WATCHMAN left atrial appendage closure therapy. Prepared for the December 11, 2013 meeting of the Circulatory System Devices Panel. 2013. Available at:. Accessed January 21, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM377356.pdf.
26. Reddy V.Y., Holmes D., Doshi S.K., et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 2011, 123(4):417-424.
27. Kar S., Doshi S., Swarup V., et al. Long term efficacy of left atrial appendage closure with WATCHMAN device. Eur Heart J 2013, 34(Suppl 1).
28. Dewilde W.J., Oirbans T., Verheugt F.W., et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013, 381(9872):1107-1115.
29. FDA. Brief summary of the Circulatory System Devices panel meeting - December 11, 2013. 2013. Available at:. Accessed January 21, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/CirculatorySystemDevicesPanel/UCM378634.pdf.
30. Reddy V.Y., Doshi S.K., Sievert H., et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) trial. Circulation 2013, 127(6):720-729.
31. Viles-Gonzalez J.F., Kar S., Douglas P., et al. The clinical impact of incomplete left atrial appendage closure with the Watchman device in patients with atrial fibrillation: a PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) substudy. J Am Coll Cardiol 2012, 59(10):923-929.
32. Cooper N.J., Sutton A.J., Lu G., et al. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006, 166(12):1269-1275.
33. Camm A.J., Lip G.Y., De Caterina R., et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012, 14(10):1385-1413.
34. Alli O., Doshi S., Kar S., et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. J Am Coll Cardiol 2013, 61(17):1790-1798.
35. Reddy V.Y., Mobius-Winkler S., Miller M.A., et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). J Am Coll Cardiol 2013, 61(25):2551-2556.
36. Massarenti L., Yilmaz A. Incomplete endothelialization of left atrial appendage occlusion device 10 months after implantation. J Cardiovasc Electrophysiol 2012, 23(12):1384-1385.
37. Plicht B., Konorza T.F., Kahlert P., et al. Risk factors for thrombus formation on the Amplatzer Cardiac Plug after left atrial appendage occlusion. JACC Cardiovasc Interv 2013, 6(6):606-613.
38. Eikelboom J.W., Connolly S.J., Brueckmann M., et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013, 369(13):1206-1214.
39. Park J.W., Bethencourt A., Sievert H., et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv 2011, 77(5):700-706.
40. Lam Y.Y. A new left atrial appendage occluder (Lifetech LAmbre device) for stroke prevention in atrial fibrillation. Cardiovasc Revasc Med 2013, 14(3):134-136.